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SUMMARY 
 
 The growth factors EGF and bFGF are indispensable for maintaining the 
self-renewal and multipotency of neural stem cells residing in developing mammalian 
telencephalon. Cortical progenitor cells (CPCs) proliferate and differentiate into 
neuronal progenitors in response to bFGF at early stages of embryonic cortical 
development and into glial progenitors in response to EGF at the late stages. The EGF 
receptor (EGFR), a member of the receptor tyrosine kinase family, is expressed in the 
embryonic cortex, and its expression levels are low during the early period and high 
during the late period. EGFR promotes the differentiation and proliferation of astrocytes 
at late embryonic and neonatal stages of cortical development. Thus, the temporal and 
spatial differences in EGFR expression contribute to the fate diversification of CPCs by 
changing their responsiveness to EGF during normal cortical development. However, 
there is limited information about regulatory mechanisms of EGFR signaling in CPCs.	
Necdin is expressed abundantly in postmitotic neurons and moderately in CPCs. Necdin 
interacts with the NGF receptor TrkA, another receptor tyrosine kinase, to promote 
differentiation and survival of sensory neurons. Moreover, a study using yeast 
two-hybrid screening has identified necdin as one of the EGFR-interacting proteins. 
These findings prompted me to investigate the physical and functional interactions 
between EGFR and necdin in CPCs.  
 In the present study, I examined whether necdin interacts with EGFR in primary 
NPCs and controls gliogenesis. Primary NPCs were prepared from mice at embryonic 
day 14.5 and cultured in the presence of bFGF for 4 days. Immunocytochemical data 
showed that necdin was expressed in NPCs and co-localized with EGFR in the 
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cytoplasm after EGF treatment. Co-immunoprecipitation assay revealed that necdin 
bound to autophosphorylated EGFR but not to unphosphorylated EGFR. Necdin 
interacted directly with the tyrosine kinase domain (TKD) of EGFR, and deletion of the 
EGFR C-terminal domain enhanced the interaction, suggesting that the 
unphosphorylated C-terminal tail interferes with the interaction between necdin and the 
TKD. Necdin failed to affect EGF-dependent EGFR autophosphorylation in NPCs but 
reduced the interaction between EGFR and Grb2, an adaptor protein that activates the 
ERK1/2 pathway. In NPCs prepared from necdin-null mice, phosphorylated ERK1/2 
levels were significantly increased. Furthermore, in necdin-null CPCs, astrocyte 
differentiation induced by the gliogenic cytokine cardiotrophin-1 was significantly 
accelerated in the presence of EGF, and inhibition of EGFR/ERK signaling abolished 
the acceleration. Moreover, necdin strongly suppressed astrocyte differentiation induced 
by overexpression of EGFR or its ligand binding-defective mutant equivalent to a 
glioblastoma-associated EGFR variant. These results suggest that necdin acts as an 
intrinsic suppressor of the EGFR/ERK signaling pathway in EGF-responsive CPCs to 
restrain astroglial development in a cell-autonomous manner. 
 
PUBLICATION 
Fujimoto, I., Hasegawa, K., Fujiwara, K., Yamada, M., and Yoshikawa, K.,  
Necdin controls EGFR signaling linked to astrocyte differentiation in primary cortical 
progenitor cells, Cellular Signalling, 28:94-107 (2016) 
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I. INTRODUCTION 
I-1. General introduction 
I-1-1. EGF and cortical development 
In the 1950s, epidermal growth factor (EGF) was incidentally discovered by 
Stanley Cohen during the course of studies on the nerve growth factor. Since this 
discovery, a lot of biological effects of EGF have been found. In particular, EGF and 
basic fibroblast growth factor (bFGF, also known as FGF-2), another major growth 
factor, are indispensable for maintaining the self-renewal and multipotency of neural 
stem cells residing in developing mammalian telencephalon (Reynolds et al., 1992; 
Tropepe et al., 1999; Maric et al., 2003; Kilpatrick and Bartlett, 1995). Cortical 
progenitor cells (CPCs) change their responses to growth factors at different time points 
of development. CPCs proliferate and differentiate into neuronal progenitors in 
response to bFGF at early stages of embryonic cortical development and into glial 
progenitors in response to EGF at the late stages (Burrows et al., 1997; Qian et al., 
2000; Lillien and Raphael, 2000; Sun et al., 2005). bFGF and EGF concentrations vary 
during development and CPCs respond differently to different concentrations of the 
same molecule (Fig. I.1). At the early stages, CPCs have no reactivity to EGF (Tropepe 
et al., 1999; Qian et al, 2000; Zhu and Parada, 2002; Gritti et al., 1999). As the stage 
progresses, the concentration of bFGF becomes high, leading to the induction of EGF 
receptor (EGFR) of CPCs (Qian et al., 1997; Powell et al., 1991). These temporal 
changes of CPCs in the responsiveness to EGF and bFGF are involved in the generation 
of specific cell types during cortical development (Temple, 2001). 
 6 
I-1-2. EGFR and its signaling pathway 
 The EGF receptor (EGFR, also known as ErbB1/HER1) belongs to a receptor 
tyrosine kinase family, including ErbB2/Neu/HER2, ErbB3/HER3 and ErbB4/HER-4 
(Schlessinger, 2002). The ligands for EGFR include EGF, transforming growth 
factor-alpha (Derynck et al., 1984), amphiregulin (Plowman et al., 1990), betacellulin 
(Sasada et al., 1993), heparin-binding EGF (Higashiyama et al., 1997), and epiregulin 
(Toyoda et al., 1997). Ligand binding to EGFR extracellular domain induces the 
formation of receptor homo- and heterodimers and the activation of the intrinsic protein 
tyrosine kinase domain (TKD), resulting in autophosphorylation on several tyrosine 
residues within the carboxy-terminal tail (Schlessinger, 2002; Yarden and Sliwkowski, 
2001).  Lysine (K) at the amino acid position 723 (K723) of EGFR is critical site for 
ATP binding activity and indispensable for EGFR autophosphorylation (Ewald et al., 
2001). Autophosphorylated tyrosine (Y) residues act as specific binding sites for 
proteins containing Src-homology 2 (SH2) domains such as Grb2, Shc, and PLCγ. 
Phosphorylated EGFR interacts with the adaptor protein Grb2 at Y1068 and Y1086 
(indirectly at Y1173 via Shc); Shc at Y994, Y1148, and Y1173; PLCγ at Y994, Y1086 
and Y1173, the cytoplasmic tyrosine kinases Src and Abl at Y1086; the phosphatases 
PTP1B at Y994 and Y1148; and SHP-1 at Y1173 (Batzer et al., 1994; Novak et al., 
2001; Sibilia et al., 2007). Y845 and Y1101 are phosphorylated by c-Src (Tice et al., 
1999; Biscardi et al., 1999) (Fig. I.2). The major downstream signaling pathways 
regulated by EGFR are Ras-Raf-MEK-ERK1/2 pathway that mainly regulates 
proliferation and differentiation and the PI3K-Akt-mTOR cascade that acts as 
pro-survival and anti-apoptotic pathways (Yarden and Sliwkowski, 2001; Batzer et al., 
1994; Sibilia et al., 2007) (Fig. I.3). 
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I-1-3. Negative feedback regulation of EGFR signaling 
	 	 The attenuation of these signaling pathways is essential to maintain the signaling 
homeostasis. Termination of EGFR signaling occurs via endocytosis and lysosomal 
degradation, which are in part regulated by ligand-induced multiple EGFR 
monoubiquitylation, but not polyubiquitylation (Dikic and Giordano, 2003; Haglund et 
al., 2003; Mosesson et al., 2003). Cbl, a ubiquitin ligase for EGFR, is recruited to 
phosphorylated EGFR at the plasma membrane, and remains associated with activated 
EGFR throughout the endosomal compartment (de Melker et al., 2001). EGFR 
ubiquitination, which is regulated in a ligand concentration-dependent manner, 
correlates with the differential recruitment of EGFR into distinct endocytic pathways 
(Woelk et al. 2006; Acconcia et al., 2009). At low EGF concentrations, EGFR is almost 
exclusively internalized through the clathrin-dependent pathway without ubiquitination. 
At higher EGF concentrations, a substantial fraction of EGFR is endocytosed through a 
clathrin-independent, lipid raft-dependent pathway, and undergoes ubiquitination 
(Sigismund et al., 2005). Endocytosis ultimately leads to the extinction of the EGFR 
activity through degradation of ligand-receptor complexes in the lysosome. 
 
I-1-4. EGFR singling-inducible feedback inhibitors 
	 	 In mammalian cells, four EGFR inducible feedback inhibitors (IFIs) LRIG1, MIG6 
(also known as RALT and ERRFI1), SOCS4 and SOCS5 have been reported to date 
(Segatto et al., 2011). All EGFR IFIs bind to EGFR directly to suppress the receptor 
signaling. LRIG1 binds to the extracellular region of the EGFR in a ligand-independent 
manner and promotes ligand-dependent ubiquitination of EGFR (Gur et al., 2004). 
SOCS4 and SOCS5, which includes an SH2 domain, bind to the EGFR in a 
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ligand-independent fashion (Kario et al., 2005; Nicholson et al., 2005). However it 
remains unclear how the SH2 domain of SOCS4 and SOCS5 is recruited to the EGFR 
in the absence of ligand-induced receptor tyrosine phosphorylation. The inhibition of 
EGFR signaling by SOCS4 and SOCS5 might be accomplished upon EGFR 
ubiquitination in both active and inactive states by an unidentified E3 ligase that is 
recruited to the SOCS-box-bound elongins B and C, subunits of the transcription factor 
B complex (Kario et al., 2005; Segatto et al., 2011). MIG6 binds to ligand-activated 
EGFR TKD and inhibits downstream EGFR signaling, including the 
Ras-Raf-MEK-ERK1/2 and the PI3K-Akt-mTOR pathways (Anastasi et al., 2003; Zhan 
et al., 2007). MIG6-bound EGFR is endocytosed and eventually degraded at the 
lysosome (Frosi et al., 2010; Madshus and Stang, 2009). 
 
I-1-5. Inactive and active states of EGFR 
	 	 Activation of the TKD of EGFR is controlled primarily by allosteric interactions 
between two TKDs; the TKD of one receptor molecule (the activator) activates the 
TKD of a second receptor (the receiver)(Zhang et al., 2006; Jura et al., 2009). The 
EGFR TKD is consist of N-terminal lobe (N-lobe) and C-terminal lobe (C-lobe) 
(Fig.1.4A). The TKD exhibits marked conformational changes when activated or 
mutated. The smaller N-lobe, largely constituted by β-sheet and the highly conserved C 
helix, contributes predominantly to the conformational change of the ATP-binding 
pocket (Fig. I.4B). The C-lobe, which is larger than the N-lobe, is mostly helical. ATP 
binds to the deep cleft between the lobes located near a highly conserved N-lobe 
structure known as the phosphate-binding loop (P-loop), which contains a conserved 
glycine-rich/sequence motif (GXGXφG). The kinases take two conformations in active 
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and inactive states (Fig. I.4B). The activation loop (A-loop), which is phosphorylated in 
the active state, serves as a platform (Nie et al., 2012).  
 
I-1-6. EGFR and cancers 
	 	 In numerous cancers such as glioblastoma, breast cancer, and non-small-cell lung 
cancer (NSCLC), there is often a transforming deregulation of EGFR signal 
transduction (Sibilia et al., 2007). Although several EGFR mutations have been 
described, the most common extracellular mutation is EGFRvIII (also known as 
de2-7EGFR). EGFRvIII is a tumor-specific mutation that results from in-frame deletion 
of 801 base pairs spanning exons 2-7 encoding the protein-coding sequence (Jungbluth 
et al., 2003; Voldborg et al., 1997; Wikstrand et al., 1995). This deletion removes 267 
amino acids from the extracellular domain, creating a junction site between exon 1 and 
8 (Yamazaki et al., 1990; Humphrey et al., 1988). Single point mutations in exon 21, for 
example L858R and G719S, account for approximately 50% of EGFR-TKD activating 
mutations (Kumar et al., 2008). Therefore, EGFR have been intensely pursed as 
therapeutic targets (Holbro and Hynes, 2004). The small-molecule gefitinib (Iressa) is 
the first EGFR-targeted inhibitor that received approval for the treatment of NSCLC. To 
date, several antibodies directed against the extracellular domain of EGFR and tyrosine 
kinase inhibitors (TKIs) that suppress the activity of the EGFR TKD are in clinical use 
or at advanced developmental stages. The treatment of tumor cells with these agents 
affects many of the intracellular pathways essential for cancer development and 
progression (Hynes and Lane, 2005).  
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I-2. Specific Introduction 
I-2-1. Necdin and MAGE family 
 Necdin (Neurally differentiated embryonal carcinoma derived protein) was 
originally identified from a subtraction cDNA library of neurally differentiated P19 
embryonal carcinoma cells (Maruyama et al., 1991). Necdin is a 325-amino acids 
residues protein, containing highly acidic and proline-rich regions at the N-terminal 
regions (1-100 amino acids) and MAGE homology domain (MHD) at rest of regions 
(101-325 amino acids) (Taniura et al., 1998). Necdin is belongs to the MAGE 
(melanoma antigen) family protein. A group of MAGE genes such as MAGE-A, B, and 
C are classified as Type I MAGE proteins expressed in cancer and germ cells. In 
contrast, Type II MAGE proteins including necdin, MAGE-D, E, F, G, and H are 
expressed in normal cells and tissues (Barker and Salehi, 2002). In fact, Necdin is 
expressed abundantly in postmitotic neurons and moderately in neural precursor cells 
(Uetsuki et al., 1996; Huang et al., 2013; Minamide et al., 2014). Necdin is also 
expressed in non-neuronal cells such as skeletal and smooth muscle, chondrocytes, 
adipocytes, and skin fibroblasts (Gérard et al., 1999; Yoshikawa, 2000; Hu et al.,  
2003; Brunelli et al., 2004; Kuwajima et al., 2004; Fujiwara et al., 2012). It is 
noteworthy that necdin is preferentially expressed in postmitotic neurons and 
non-neuronal cells. Ectopic expression of necdin strongly suppresses the proliferation of 
many cell lines such as NIH3T3 cells, osteosarcoma SAOS-2 cell, and N1E-115 
neuroblastoma cells (Hayashi et al., 1995; Taniura et al., 1999; Kobayashi et al., 2002). 
 
I-2-2. Biological function of necdin 
	 	 The biological functions and molecular mechanisms have been elucidated through 
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identification of necdin binding proteins. Necdin interacts with cell cycle regulatory 
transcripton factors E2Fs, p53, Msx, and HIF-2α to suppress transcriptional activation 
and cell cycle progression (Taniura et al., 1998; Huang et al., 2013; Kuwajima et al., 
2004; Kobayashi et al., 2002; Taniura et al., 1999). Necdin also interacts with p75NTR, 
TrkA, Dlx, and Sirt1 to promote neuronal differentiation and survival or to suppress 
apoptosis (Kuwako et al., 2004; Kuwako et al., 2005; Hasegawa and Yoshikawa 2008; 
Hasegawa et al., 2012). In addition, the calcium-binding protein NEFA, hnRNP-U 
(heterogenous nuclear ribonucleoprotein U), SV40 large T antigen, adenovirus E1A, 
Fez1, Bmi1, and PIAS1 have been identified as necdin-binding proteins (Minamide et 
al., 2014; Taniguchi et al., 2000; Taniura and Yoshikawa 2002; Lee et al., 2005; Gur et 
al., 2014). Thus, necdin have diverse functions through association with proteins which 
regulate the cell cycle, apoptosis and differentiation in the nervous system and 
non-neuronal tissues.  
	 	 Necdin interacts with the NGF receptor TrkA, a receptor tyrosine kinase (Kuwako 
et al., 2005). Moreover, a study using yeast two-hybrid screening has identified necdin 
as one of the EGFR-interacting proteins (Deribe et al., 2009). These findings led us to 
investigate the physical and functional interactions between EGFR and necdin in CPCs.   
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Figure I.1  Neurogenesis and gliogenesis during cortical development.  
CPCs alter their responses to growth factors at different stages of corticogenesis 
(adapted from Temple S, 2001).  
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Figure I.2 Domain structure of mouse EGFR. 
Sequence information was obtained from NCBI NM 207655.2. 
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Figure I.3 EGFR signaling pathway. 
The Ras-Raf-MEK-ERK1/2 pathway mainly regulates proliferation and differentiation, 
while the PI3K-Akt-mTOR pathway mainly regulates survival and apoptosis. 
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Figure I.4  Ribbon representation of the two crystalized conformations 
of EGFR TKD. 
(A) Primary structure of EGFR TKD. Sequence information was obtained from NCBI 
NM 207655.2. L1/2, ligand-biding domain 1/2; TM, transmembrane domain; CT, 
C-terminal tail. (B) Crystal structures of inactive EGFR TKD (PDB 4G5J)(left) and 
active EGFR TKD in complex with ATP analog-peptide (PDB 2GS6)(right). 
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II. EXPERIMENTAL PROCEDUES 
II-1. Primary cortical progenitor cells 
 Neocortical tissues were dissected from mouse embryos at embryonic day (E) 14.5, 
incubated for 5 min at 37℃ in Ca2+/Mg2+-free glucose-supplemented HBSS with 0.05% 
trypsin, dissociated in DMEM supplemented with 10% fetal bovine serum, and 
centrifuged at 200 × g for 3 min to obtain cell pellets. Resuspended cells were incubated 
at 37℃ under humidified 5% CO2 conditions in CPC medium containing DMEM/F12 
(Thermo Fisher Scientific), B-27 (1:50 dilution; Thermo Fisher Scientific), 14 mM 
sodium bicarbonate, 1 mM N-acetyl-L cysteine, 33 mM D (+)-glucose, 1 mg/ml bovine 
serum albumin, 2 mM GlutaMAX (Thermo Fisher Scientific), kanamycin/penicillin, 
and 20 ng/ml bFGF (PeproTech). CPCs were grown as floating spheres, dispersed with 
TrypLE (TrypLE Select; Thermo Fisher Scientific), and passaged every 48 h unless 
stated otherwise. Necdin gene (Ndn) mutant mice were generated and maintained as 
described previously (Kuwako et al., 2005). Heterozygous male mice (Ndn+/-)(>25 
generations in the ICR background) were crossed with wild-type female mice 
(Ndn+/+)(Japan SLC) to obtain wild-type (Ndn+m/+p) and paternal Ndn-deficient 
(Ndn+m/-p) littermates. All mice were housed in a 12 h light/dark cycle with room 
temperature at 23 ± 3℃. Pregnant female mice at gestation day 14.5 were sacrificed by 
cervical dislocation, and embryos were collected. Genotypes of all mice were analyzed 
for mutated Ndn locus. The study was approved by the Animal Experiment Committee 
(Approval No. 24-04-0) and Recombinant DNA Committee (Approval No. 3642) of 
Institute for Protein Research, Osaka University, and were performed in accordance 
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with national, institutional, and the ARRIVE guidelines. 
 
II-2. Immunoblot analysis   
 CPCs and brain tissues were homogenized with a lysis buffer containing 10 mM 
Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM EDTA, 1% IGEPAL CA-630 (MP 
Biomedicals), 10% glycerol, and protease inhibitors (Complete, Roche Diagnostics). 
The protein concentration was determined by the Bradford method (Bio-Rad). Proteins 
(10 µg per lane) were separated by 9% SDS-PAGE, and electroblotted to 
polyvinylidene difluoride membranes (Immobilon, Merck Millipore). Membranes were 
incubated with primary antibodies against EGFR (1005; 1:100; Santa Cruz 
Biotechnology), necdin (NC243; 1:3000)(Niinobe et al., 2000), nestin (ST-1; 
1:1000)(Aizawa et al., 2011), γ-tubulin (GTU-88; 1:1000; Sigma-Aldrich), 
phospho-EGFR (Tyr1068)(D7A5; 1:1000; Cell Signaling Technology), PCNA (PC10; 
1:1000; Santa Cruz Biotechnology), Myc (9E10; 1:10), phospho-ERK1/2 (E10; 1:1000; 
Cell Signaling Technology), ERK1/2 (K-23; 1:3000; Santa Cruz Biotechnology), 
phospho-Akt (193H12; 1:500; Cell Signaling Technology), Akt (1:500; Cell Signaling 
Technology), Grb2 (C-7; 1:300; Santa Cruz Biotechnology), Sos1 (C-23; 1:1000; Santa 
Cruz Biotechnology), glial fibrillary acidic protein (GFAP)(1:1000; gift from Dr. 
Seiichi Haga, Tokyo Metropolitan Institute of Medical Science), and FLAG (M2; 
1:500; Sigma-Aldrich),. After incubation with peroxidase-conjugated IgGs (Cappel), the 
proteins were visualized by chemiluminescence method (Chemiluminescence Reagent 
Plus, PerkinElmer). Signal intensities were measured by densitometry and quantified 
using NIH ImageJ 1.46 software.   
 
 18 
II-3. Immunocytochemistry   
 Primary CPCs were dispersed with TrypLE Select, plated onto 24-well plates 
precoated with poly-L-ornithine (Sigma-Aldrich), and incubated for 3 h. Cells were 
fixed with 10 % formalin solution at room temperature for 20 min and permeabilized 
with methanol at room temperature for 20 min. For EGFR staining, cells were fixed 
with 4% paraformaldehyde in phosphate buffer (pH 7.4) and permeabilized with 0.02% 
Tween 20 in PBS at room temperature for 10 min. Fixed cells were incubated with 
primary antibodies at 4℃ overnight, and with secondary antibodies at room temperature 
for 90 min. The primary antibodies used are against EGFR (1005; 1:50), necdin (GN1; 
1:1000)(Kuwako et al., 2005), nestin (ST-1; 1:1000), phospho-EGFR (D7A5; 1:100), 
GFAP (1:1000), βIII-tubulin (5G8; 1:1000; Promega), and RFP (3G5, 1:100, MBL). 
The secondary antibodies Alexa 488-conjugated anti-rabbit IgG (1:500), Alexa 
555-conjugated anti-guinea pig IgG (1:500), and Alexa 555-conjugated anti-rabbit IgG 
(1:500) were purchased from Molecular Probes. Nuclear DNA was counterstained with 
3.3 µM Hoechst 33342 (Sigma-Aldrich). Images were observed with a fluorescence 
microscope (BX51, Olympus) equipped with charge-coupled device camera system 
(DP73, Olympus) or by confocal laser scanning microscopy (FV1000 BX61, Olympus), 
and processed using Adobe Photoshop CS5 software. 
 
II-4. Coimmunoprecipitation assay 
 For detection of endogenous binding between necdin and EGFR, lysates of CPCs 
(1 mg protein) cultured in the CPC medium for 4 days were incubated with guinea pig 
anti-necdin IgG (GN1; 1:10)(Kuwako et al., 2005) or preimmune IgG. Bound proteins 
were isolated with Dynabeads protein A (Thermo Fisher Scientific) and detected by 
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immunoblotting with antibodies against phospho-EGFR (D7A5; 1:1000), EGFR (1005; 
1:100) and necdin (NC243; 1:3000). For interactions between necdin and EGFR 
mutants in transfected cells, HEK293A cells were transfected with combinations of 
expression vectors by the calcium phosphate method and harvested after 24 h. Cell 
lysates (150 µg protein) were incubated at 4℃ for 2 h with antibodies against Myc 
(9E10; 1:4) and necdin (NC243; 1:100), pelleted with Protein A-Sepharose (GE 
Healthcare), separated by 9% SDS-PAGE, and detected by immunoblotting. Full-length 
mouse EGFR cDNA (NCBI NM 207655.2) was synthesized by RT-PCR from mRNA 
expressed in CPCs. cDNAs encoding EGFR deletion mutants and its point mutants 
were generated using synthetic oligonucleotide primers based on their sequence 
information (NCBI NM 207655.2) and subcloned into 6xMyc-pcDNA3.1+. For 
interactions of EGFR with Grb2 and Sos1, primary CPCs prepared from E14.5 mice 
were cultured for 4 days and treated with EGF (10 ng/ml) for 5 min. CPC lysates (500 
µg protein) were incubated with antibodies to Grb2 (C-7; 1:100) and Sos1 (C-23; 1:100). 
Bound proteins were pelleted with Protein A-Sepharose and detected by 
immunoblotting with the antibody to EGFR (1005; 1:100).  
  
II-5. In vitro binding assay 
 The tyrosine kinase domain (TKD) of EGFR and its deletion mutants were 
generated using synthetic oligonucleotide primers based on their sequence information 
(NCBI NM 207655.2) and subcloned into pMAL-C2 vector to make maltose binding 
protein (MBP) fusion proteins. MBP-fused proteins were affinity-purified with amylose 
resin (New England Biolabs) and incubated with His-tagged necdin (200 ng) at 4°C for 
30 min in 0.5 ml of the binding buffer containing 20 mM Tris-HCl (pH7.5), 200 mM 
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NaCl, and 1 mM EDTA (Hasegawa and Yoshikawa, 2008). After washing, bound 
His-tagged necdin was eluted with 20 mM maltose and detected by immunoblotting 
with anti-necdin antibody. MBP fusion proteins were detected by Coomassie Brilliant 
Blue staining. 
 
II-6. Cell proliferation assay 
 Primary CPCs were prepared from E14.5 mice and incubated for 48 h. Cells (2 x 
105 cells) were replated in 35-mm dishes, incubated in the presence or absence of 20 
ng/ml EGF for another 48 h, and harvested for manual cell counting. For EdU 
incorporation, CPCs at 4 day in vitro (DIV) were plated onto poly-L-ornithine-coated 
coverslips. Cells were cultured in the CPC medium supplemented with 10 ng/ml EGF 
for 24 h and fixed with 10% formalin solution at room temperature for 20 min, and 
permeabilized with methanol at room temperature for 20 min. EdU (Invitrogen, 
A10044; 10 µM) was added to the CPC medium 4 h before fixation. Fixed cells were 
incubated for 30 min with 3.3 µM Hoechst 33342 (Sigma-Aldrich) and then with EdU 
detection cocktail (A10044, Invitrogen) at room temperature for 15 min. 
 
II-7. Cell differentiation assay 
 For astrocyte differentiation assay, CPCs cultured for 48 h in the CPC medium 
were incubated in the presence and absence of 20 ng/ml EGF for 48 h. CPCs were 
dissociated and plated onto poly-L-ornithine-coated coverslips in the CPC medium 
supplemented with 50 ng/ml cardiotrophin-1 (CT-1)(PeproTech) for 48 h. 
GFAP-immunopositive cells were detected by immunocytochemistry as above. For 
neuronal differentiation assay, CPCs cultured for 48 h in the CPC medium were 
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incubated in the presence and absence of 20 ng/ml EGF for 48 h. CPCs were dissociated, 
plated onto poly-L-ornithine-coated coverslips and cultured in the CPC medium 
deprived of EGF and bFGF for 24 h. βIII tubulin-expressing cells were detected by 
immunocytochemistry as above. 
 
II-8. Kinase inhibitor assay 
 CPCs were cultured in the CPC medium for 48 h, and EGF (10 ng/ml) in the 
presence of the EGFR tyrosine kinase inhibitor gefitinib (5 µM; Cayman Chemical), 
mitogen-activated protein kinase kinase (MEK) inhibitor U0126 (20 µM; Merck 
Millipore) and phosphoinositide 3-kinase (PI3K) inhibitor LY294002 (20 µM; Merck 
Millipore) were added to the CPC medium 30 min before treatment with EGF. CPCs 
were treated with EGF (10 ng/ml) for 5 min and harvested for immunoblot analysis of 
phospho-EGFR, phospho-ERK, and phospho-Akt. For GFAP expression assay, CPCs 
were treated with EGF and the kinase inhibitors for 6 h, replated in 35-mm dish 
precoated with poly-L-ornithine, and treated with CT-1 (50 ng/ml) for 48 h. Expression 
of GFAP was analyzed by immunoblotting. 
 
II-9. In vitro electroporation. 
 CPCs were prepared from E14.5 mice and cultured for 48 h. CPCs were 
centrifuged and resuspended at 5 x 106 cells in 100 µl of Opti-MEM containing 
expression vectors (total DNA, 20 µg). Electric pulses (pore pulse; 125V/10 msec x 1: 
transfer pulse; 20V/50 msec/50 msec interval; 10 cycles) were applied to the cell 
suspension in 2-mm gap cuvette using a pulse generator (CUY21-EDIT II, BEX). 
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cDNA encoding EGFR lacking residues 6-273 (EGFRΔNT) was generated using 
synthetic oligonucleotide primers based on their sequence information (NCBI NM 
207655.2) and subcloned into 6xMyc-pcDNA3.1+. cDNAs for EGFR, EGFR mutants 
(KR and ΔNT), FLAG-tagged mouse necdin, necdinΔEB (residues 144-184 deletion 
mutant)(Taniura et al., 2005), FLAG-tagged human MAGEA1(Gur et al., 2014), and 
td-Tomato (ptdTomato-N1, Clontech) were transfected into primary CPCs. Transfection 
efficiency was ~70% as analyzed 12 h after transfection by fluorescence 
immunocytochemistry for td-Tomato expression. Expression of transfected cDNAs was 
analyzed by immunoblotting 12 h after electroporation. For GFAP expression, 
transfected CPCs were cultured for 24 h in the CPC medium and treated with CT-1 (50 
ng/ml) for 48 h. GFAP expression of transfected CPCs was analyzed by 
immunoblotting and fluorescence immunocytochemistry using antibodies to GFAP and 
RFP for td-Tomato. 
 
II-10. Quantitative RT-PCR 
	 	 Total RNA was extracted with phenol and guanidine thiocyanate mixture (TRI 
Reagent, Molecular Research Center), and contaminating DNA was digested with RQ1 
RNase-free DNAase (Promega). cDNA was synthesized from total RNA (2 µg) using 
Transcriptor First Strand cDNA Synthesis Kit (Roche Diagnostics). An aliquot of 
cDNA mixture (0.2%) was used as PCR templates. Primers used for quantitative 
real-time PCR are as follows: EGF (forward, 5’-caagtgatggatagacgtga-3’; reverse, 
5’-cagggatggataacggttag-3’), Gapdh (forward, 5’-gaatacggctacagcaa-3’; reverse, 
5’-gcagcgaactttattgatggta-3’), cFOS (forward, 5’-agttagtagagcatgtgagt-3’; reverse, 
5’-tgaaggactacagtacatgg-3’), cJUN (forward, 5’-ttgtaagtgccaggctagac-3’; reverse, 
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5’-catgcagggtatctattccaca-3’), EGR1 (forward, 5’-catgtgtcagagtgttgttccgt-3’; reverse, 
5’-agcgcattcaatgtgtttataagcc-3’), EGR2 (forward, 5’-tcaagagaatggaagtgcaa-3’; reverse, 
5’-gccatacttaaacccaagga-3’), IEX1 (forward, 5’-gcttttctccagcaacatcc-3’; reverse, 
5’-ttacatacacccctccttcac-3’). RT-PCR products were quantified using FastStart DNA 
MasterPLUS SYBR Green I kit (Roche Diagnostics). Melting curves were analyzed to 
confirm a single species of each PCR product. Gapdh cDNA was used as an internal 
control to quantify the relative expression of each cDNA. 
 
II-11. Statistics  
 Statistical significance was tested using an unpaired Student’s t test, one-way 
ANOVA followed by Tukey-Kramer post hoc test. A significance of P < 0.05 was 
required for rejection of the null hypothesis. 
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III. RESULTS 
III-1. EGFR expression is induced by bFGF in primary CPCs 
 We first analyzed the expression levels of EGFR and necdin in primary CPCs 
prepared from the mouse cortex at E14.5 by immunoblotting (Fig. III.1A). When CPCs 
were treated with bFGF for up to 4 DIV, the EGFR levels increased when incubated in 
the presence of bFGF for 2 days or more, whereas necdin was expressed in a 
constitutive manner. The neural stem/progenitor cell marker nestin was also expressed 
in these CPCs. Immunocytochemical analysis showed that EGFR was hardly detectable 
in CPCs at 1 DIV but was clearly detected at the plasma membrane and in the 
cytoplasm at 4 DIV, whereas necdin was predominantly cytoplasmic at 1 and 4 DIV 
(Fig. III.1B). Thus, we used CPCs cultured in the bFGF-supplemented CPC medium 
for 4 days or more in the following experiments. 
 We then analyzed autophosphorylation of EGFR in EGF-stimulated CPCs. 
Autophosphorylation of EGFR (phospho-EGFR), which was detected with a 
site-specific anti-phosphotyrosine antibody against pY1068, increased markedly in 
CPCs 5 min after EGF treatment (Fig. III.2A). The levels of the total EGFR and 
phospho-EGFR levels decreased at 120 min. Consistent with the immunoblot results, 
the phospho-EGFR immunoreactivity increased in the cytoplasm at 5 and 30 min, and 
both phospho-EGFR and total EGFR levels were reduced at 120 min (Fig. III.2B). 
These results suggest that autophosphorylated EGFR undergoes degradation in primary 
CPCs.  
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III-2. Necdin and phosphorylated EGFR colocalize in primary CPCs 
 We investigated whether EGFR and necdin are colocalized in primary CPCs (Fig. 
III.3A). Immunocytochemistry showed that EGFR was localized at the plasma 
membrane and in the cytoplasm of CPCs. When CPCs were treated with EGF, EGFR 
was accumulated in the cytoplasm, and the EGFR immunoreactivity overlapped 
partially with the necdin immunoreactivity. We also analyzed the colocalization of 
autophosphorylated EGFR and necdin in CPCs (Fig. III.3B). The phospho-EGFR 
immunoreactivity was hardly detected in unstimulated CPCs but increased appreciably 
in the cytoplasm of EGF-treated CPCs, where it overlapped partially with that of necdin. 
Furthermore, three-dimensional analysis of confocal images demonstrated that 
phospho-EGFR and necdin were colocalized under the plasma membrane (Fig. III.3C). 
We then analyzed the interaction between endogenous necdin and EGFR in CPCs by 
coimmunoprecipitation assay (Fig. III.4). Phospho-EGFR and total EGFR were 
coprecipitated with necdin in the lysate of wild-type CPCs treated with EGF. Although 
expression levels of total EGFR were similar between EGF-treated and untreated CPCs, 
necdin failed to interact with EGFR in wild-type CPCs without EGF treatment. This 
indicates that necdin binds only to phospho-EGFR. Together, these results suggest that 
endogenous necdin and phospho-EGFR form a stable complex in EGF-stimulated 
CPCs. 
 
III-3. Necdin interacts with the TKD of EGFR  
 To characterize the interaction between necdin and EGFR, we performed the 
coimmunoprecipitation assay using transfected HEK293A cells. In mouse EGFR 
cDNA-transfected HEK293A cells, overexpressed EGFR underwent ligand-independent 
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autophosphorylation (Fig. III.5A). To validate the assay system, we tested the 
interactions of necdin with wild-type EGFR and its kinase dead (K723R) mutant using 
the adaptor protein Grb2 as a positive control (Fig. III.5B). Both necdin and Grb2 
bound preferentially to wild-type EGFR, suggesting that necdin binds to EGFR only in 
its active state. 
 We then examined the interactions of necdin with EGFR deletion mutants that lack 
126 and 240 amino acid residues of the C-tail containing autophosphorylated tyrosine 
residues (Fig. III.6A). Necdin was expressed in transfected HEK293A cells as major 42 
kDa and minor 37 kDa proteins (the minor protein is presumably a degraded product of 
the 42 kDa protein). In this assay, necdin bound to wild-type EGFR (WT) and an EGFR 
mutant lacking C-terminal 126 residues (WTΔC126) (Fig. III.6B). Notably, necdin 
strongly bound to the deletion mutants WTΔC240 and KRΔC240 lacking the entire 
C-terminal 240 residues. These results suggest that the C-tail of EGFR interferes with 
the interaction between necdin and EGFR. Necdin failed to interact with an EGFR 
mutant (ΔC497) lacking both the C-tail and the tyrosine kinase domain (TKD)(residues 
690-946), indicating that necdin binds to the TKD. 
 To determine the necdin-binding region of the TKD, we constructed Myc-tagged 
TKD deletion mutants (Fig. III.7A). Necdin bound to wild-type TKD and the TKD KR 
mutant, but not to wild-type TKDΔC91 lacking the C-terminal 91 residues in the C-lobe 
(Fig. III.7B). In contrast, necdin strongly interacted with the C-terminal 91 residues 
(C91). The necdin-binding region was narrowed down to the C-terminal 30 residues of 
the TKD (TKD-C30). To test whether necdin directly binds to the TKD-C30 region, we 
performed in vitro pull-down assay using MBP-fused wild-type EGFR TKD (WT), 
TKD mutants (TKDΔC30 and TKD-C30), and His-tagged necdin (Fig. III.8A,B). 
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Consistent with the results of coimmunoprecipitation, His-tagged necdin bound to 
wild-type TKD and TKD-C30, but not to TKDΔC30, indicating that necdin binds 
directly to the C-terminal region (residues 917-946) of the TKD. 
 
III-4. Necdin suppresses the EGFR/ERK signaling 
 To examine whether endogenous necdin affects the tyrosine kinase activity, we 
analyzed EGF-induced autophosphorylation of EGFR in necdin-null CPCs (Fig. 
III.9A,B). Immunoblot analysis showed that phospho-EGFR levels were not 
significantly changed in necdin-null CPCs (Fig. III.9A, top panel; Fig. III.9B, top 
graph). We also examined the effects of necdin on the EGFR signaling pathways by 
analyzing the phosphorylation levels of ERK and Akt. In this analysis, minor and major 
ERK bands at 44 kDa (ERK1) and 42 kDa (ERK2) were detected. Notably, 
phospho-ERK levels in necdin-null CPCs increased ~2-fold at 5 min in response to EGF 
(Fig. III.9A, 3rd panel; Fig. III.9B, middle graph). In contrast, phospho-Akt levels 
were not significantly changed in necdin-null CPCs (Fig. III.9A, 5th panel, Fig. III.9B, 
bottom graph). 
 To investigate whether necdin affects the EGFR/RAS/ERK signaling pathway, we 
examined the interactions of EGFR with the adaptor protein Grb2 and the Grb2-binding 
RAS activator Sos1 in wild-type and necdin-null CPCs (Fig. III.10A,B). The amount of 
EGFR coprecipitated with Grb2 or Sos1 increased markedly (~2.5-fold) in necdin-null 
CPCs treated with EGF (Fig. III.10A, top and 3rd panels, Fig. III.10B). Grb2 failed to 
interact with necdin as analyzed by coimmunoprecipitation using transfected HEK293A 
(Fig. III.11). These results suggest that necdin suppresses the interaction between 
EGFR and Grb2 to downregulate the RAS/ERK signaling in CPCs.  
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III-5. Necdin suppresses proliferation of CPCs 
 Because the EGFR/ERK pathway is involved in the control of cellular proliferation, 
we next examined whether necdin affects the proliferation rate of primary CPCs (Fig. 
III.12A,B). When CPCs were treated with EGF for 48 h, the total cell number of CPCs 
increased significantly (1.37 times the wild-type control level) in necdin-null CPCs, 
whereas there was no significant difference in the absence of EGF. We also used EdU 
incorporation assay to determine the proliferation rate of CPCs prepared from wild-type 
and necdin-null mice (Fig. III.13A-C). The population of EdU+ S-phase cells in 
necdin-null CPCs increased significantly (1.35 times the wild-type control level). These 
results suggest that endogenous necdin suppresses EGF-stimulated proliferation of 
primary CPCs through inhibition of the EGFR/ERK pathway. To elucidate the 
downregulation of RAS/MEK/ERK signaling pathway, we determined the mRNA 
levels of immediate early gene in CPCs prepared from wild-type and necdin-null mice 
after EGF treatment (Fig. III.14). The cFOS mRNA level increased significantly in the 
necdin-null CPCs, whereas no significant differences in the cJUN, EGR1, and EGR2 
mRNA levels were noted between wild-type and necdin-null mice. Interestingly, the 
mRNA level of IEX1, an immediate early gene related to astrocyte differentiation (You 
et al., 2007), increased significantly in CPCs from necdin-deficient mice. 
 
III-6. Necdin suppresses astrocyte differentiation of CPCs 
 CPCs differentiate into astrocytes in response to the interleukin-6 (IL-6) family of 
cytokines such as CNTF and LIF (Bonni et al., 1997; Johe et al., 1996; Nakashima et al., 
1999). EGFR regulates the competence of CPCs to interpret LIF as an 
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astrocyte-inducing signal (Viti et al., 2003). To investigate whether necdin affects 
astrocyte differentiation of CPCs by suppressing EGFR signaling, we used 
cardiotrophin-1 (CT-1), one of the IL-6 family cytokines (Barnabe-Heider et al., 2005; 
Ochiai et al., 2001), to induce astrocyte differentiation of CPCs (Fig. III.15A-C). The 
number of GFAP+ astrocytes differentiated from necdin-null CPCs increased by 39% in 
the presence of EGF and CT-1, whereas the GFAP+ cell population was not 
significantly changed in necdin-null CPCs in the absence of EGF. These results indicate 
that endogenous necdin suppresses EGF-promoted glial differentiation via inhibition of 
the EGFR/ERK signaling.  
 In this analysis, we found that the GFAP immunoreactivity increased appreciably 
in each GFAP-expressing cell differentiated from necdin-null CPCs (Fig. III.15B). 
Thus, we analyzed the expression levels of the GFAP protein by immunoblotting (Fig. 
III.15D). EGF markedly increased expression levels of the GFAP protein in necdin-null 
CPCs treated with CT-1, indicating that the GFAP protein level correlates well with the 
extent of astrocyte differentiation. 
 We also examined neuronal differentiation of EGF-treated CPCs by withdrawing 
both bFGF and EGF (Fig. III.16A-C). EGF markedly reduced the population of 
βIII-tubulin+ neurons, suggesting that EGF prevents neuronal differentiation of CPCs. 
However, there was no significant difference in the number of differentiated 
βIII-tubulin+ neurons between wild-type and necdin-null CPCs. These observations 
suggest that necdin specifically suppresses EGF-promoted astrocyte differentiation of 
CPCs.  
 To investigate whether necdin-null mice express high GFAP levels in the cortex in 
vivo during the neonatal period, we analyzed cortical GFAP levels at postnatal day 4 by 
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immunoblotting. We found no significant difference in the GFAP level between 
wild-type and necdin-null mice (Fig. III.17A,B). Intriguingly, EGF mRNA levels in 
necdin-null cortex in vivo were reduced by 54% at E18.5, a late stage of cortical 
development when astrocyte differentiation occurs (Fig. III.17C). Expression of EGF 
mRNA in primary CPCs was also reduced by 50% (Fig. III.17D). These results suggest 
that necdin-null CPCs express low levels of EGF mRNA to prevent astrocyte 
hyperproliferation due to enhanced EGFR signaling via a negative feedback regulation.  
 
III-7. Inhibition of EGFR/ERK signaling blocks astrocyte differentiation 
 To determine whether EGF-promoted astrocyte differentiation is mediated via the 
EGFR signaling pathways in CPCs, we used the EGFR tyrosine kinase inhibitor 
(gefitinib), MEK1/2 inhibitor (U0126), and PI3K inhibitor (LY294002). We first 
examined the effects of these inhibitors on EGF-induced phosphorylation levels of 
EGFR, ERK and Akt by immunoblot analysis (Fig. III.18A). Autophosphorylation of 
EGFR was detected 5 min after EGF stimulation in CPCs treated with the MEK 
inhibitor and the PI3K inhibitor but not in those treated with the EGFR tyrosine kinase 
inhibitor. As expected, phosphorylation of ERK and Akt was hardly detected in 
EGF-stimulated CPCs treated with the inhibitors of MEK and PI3K, respectively. 
 We then analyzed the effects of these kinase inhibitors on astrocyte differentiation 
by immunoblot assay. CPCs were treated with EGF in the presence or absence of these 
inhibitors for 6 h and then with CT-1 for 48 h (Fig. III.18B). The GFAP levels in 
EGF-stimulated CPCs increased appreciably when incubated in the absence of the 
inhibitors or in the presence of the PI3K inhibitor (Fig. III.18C). These observations 
indicate that EGF-promoted astrocyte differentiation is mediated by the EGFR/ERK 
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signaling pathway in CPCs. 
 To test whether the EGFR/RAS/MEK/ERK pathway mediates EGF-promoted 
enhancement of the GFAP levels in necdin-null CPCs, we treated CPCs with EGF and 
these kinase inhibitors (Fig. III.19A,B). The EGF-dependent increase in the GFAP 
levels was significantly enhanced (1.54 times the wild-type control level) in necdin-null 
CPCs, and this enhancement was completely blocked by EGFR tyrosine kinase inhibitor 
(gefitinib) or MEK1/2 inhibitor (U0126), but not by PI3K inhibitor (LY294002). These 
results suggest that necdin suppresses astrocyte differentiation through attenuation of 
the EGFR/RAS/MEK/ERK signal transduction. 
 
III-8. Necdin suppresses EGFR-promoted astrocyte differentiation  
 Sustained activation of the EGFR/RAS/ERK pathway is involved in astrocyte 
proliferation and pathogenesis of gliomas (Nicholas et al., 2006; Zhu and Parada, 2002). 
Thus, we investigated whether astrocyte differentiation of primary CPCs is promoted by 
overexpression of EGFR and an EGFR mutant (EGFRΔNT) lacking the N-terminal 
ligand-binding domain (L1), which is equivalent to human glioblastoma-associated 
EGFR variant III (EGFRvIII) (Fig. III.20A). CPCs were transiently transfected with 
cDNAs encoding wild-type EGFR, kinase-dead K723R mutant, and EGFRΔNT by 
electroporation. Autophosphorylation of wild-type EGFR and EGFRΔNT mutant, but 
not that of the KR mutant, was detected 12 h after transfection by immunoblot analysis 
of phospho-EGFR (Fig. III.20B).  
 We analyzed whether forced expression of EGFR and EGFR mutants enhances 
astrocyte differentiation. Transiently transfected CPCs were incubated for 24 h and then 
treated with CT-1 for 48 h (Fig. III.21A). Immunocytochemistry showed that 
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overexpression of wild-type EGFR or EGFRΔNT increased the GFAP 
immunoreactivity in transfected td-Tomato+ CPCs (Fig. III.21B). These cells exhibited 
morphological characteristics of differentiated astrocytes such as extended processes 
and larger cell bodies. Consistent with these morphological changes, GFAP expression 
levels increased markedly in CPCs transfected with wild-type EGFR or EGFRΔNT as 
analyzed by immunoblotting (Fig. III.21C). 
 We then examined whether necdin prevents EGFR- or EGFRΔNT-promoted 
astrocyte differentiation of CPCs (Fig. III.22A,B). We found that a necdin mutant 
lacking residues 144-184 located in the MAGE homology domain (necdinΔEB) 
(Taniura et al., 2005) failed to interact with EGFR (Fig. III.23A,B). Thus, we used this 
EGFR binding-defective mutant as a negative control. Necdin strongly decreased the 
GFAP level to near basal level of td-Tomato+ control in EGFR-overexpressing CPCs. 
Similarly, necdin reduced the GFAP level in EGFRΔNT-overexpressing CPCs. In 
contrast, necdinΔEB had no antagonizing effects. In this analysis, neither necdin nor 
necdinΔEB affected the basal GFAP level in transfected CPCs.  
 We analyzed whether human MAGEA1, a MAGE family member expressed in 
many cancers, affects EGFR-mediated astrocyte differentiation induced by EGFR 
overexpression. MAGEA1 bound to both EGFR and kinase-dead mutant (Fig. 
III.24A,B). To determine the MAGEA1-binding region of the TKD, we constructed 
Myc-tagged TKD deletion mutants (Fig. III.25A). MAGE-A1 bound to wild-type TKD 
and TKDΔC91 lacking the C-terminal 91 residues in the C-lobe but not to TKDΔPL, 
TKDΔCH, and TKDΔAL which are important for TKD activation (Fig. III.25B). In 
contrast to necdin, MAGEA1 enhanced EGFR-induced GFAP expression, and 
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coexpression of necdin strongly antagonized the effect of MAGEA1 (Fig. III.26A,B). 
These results suggest that necdin and MAGEA1 exert opposite effects on the EGFR 
signaling.  
 We also examined the GFAP expression levels in wild-type and necdin-null CPCs 
overexpressing EGFR (Fig. III.27A,B). The GFAP levels increased by 57% in 
necdin-null CPCs overexpressing EGFR. The increase in the GFAP level was 
completely suppressed by coexpression of necdin, but not of necdinΔEB. These results 
suggest that endogenous necdin in CPCs acts as an intrinsic suppressor of astrocyte 
differentiation induced by EGFR overexpression. 
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Figure III.1 EGFR and necdin are coexpressed in primary CPCs.  
(A) CPCs were prepared from the neocortex at E14.5 and cultured in the presence of 
bFGF (bFGF+) for the indicated durations. Expression of EGFR, necdin, nestin, and 
γ-tubulin (γ-Tub) was analyzed by immunoblotting. (B) CPCs were immunostained for 
EGFR (green), necdin (red), and nestin (green) and observed by confocal microscopy. 
Nuclear DNA was counterstained with Hoechst33342 (blue) and merged with confocal 
images. Scale bar; 10 µm (in B) 
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Figure III.2 Autophosphorylation occurs by addition of EGF in primary 
CPCs. 
(A) CPCs were treated with EGF for the indicated durations. Expression of 
phospho-EGFR (pEGFR) and total EGFR (EGFR) was analyzed by immunoblotting or 
(B) immunocytochemistry. Confocal images (green) and nuclear DNA stain (blue) are 
merged. Scale bar; 5 µm (in B). 
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Figure III.3 Autophosphorylated EGFR and necdin are colocalized in 
primary CPCs.  
(A, B) Immunocytochemistry. CPCs at 4 DIV were treated with (EGF+) or without 
(EGF-) EGF for 5 min. EGFR (green)(A) or phospho-EGFR (pEGFR)(green)(B) and 
necdin (red) were immunostained and observed by confocal microscopy. 
Immunostained images and nuclear DNA stain (blue) are merged (Merge) for 
colocalization (yellow). (C) Three-dimensional analysis. CPCs were double 
immunostained for pEGFR (green) and necdin (red), and observed by confocal 
microscopy. Multiple z-stack images in XY, XZ and YZ axes are shown. Scale bars; 10 
µm (in A, B), 5 µm (in C).  
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Figure III.4 Endogenous necdin interacts with phospho-EGFR in CPCs. 
Coimmunoprecipitation assay. CPCs were prepared from wild-type (WT) and 
necdin-null (KO) mice and treated at 4 DIV with EGF (EGF+) or without (EGF-) EGF 
for 5 min. Cell lysates were immunoprecipitated with anti-necdin IgG (αNecdin IgG) or 
preimmune IgG (Pre IgG). pEGFR, EGFR, and necdin were analyzed by 
immunoblotting. Lysate, CPC lysate (10 µg).  
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Figure III.5 Autophosphorylated EGFR binds to necdin and Grb2 in 
HEK293A cells. 
(A) HEK293A cells were transfected with cDNAs for Myc-tagged EGFR and its kinase 
dead K723R mutant. Autophosphorylation was detected with antibody against 
phospho-EGFR (pEGFR). (B) HEK293A cells were transfected with cDNAs for 
Myc-tagged wild-type EGFR (WT), Myc-tagged K723R mutant (KR), FLAG-tagged 
Grb2 (FLAG-Grb2, positive control) and FLAG-tagged necdin (FLAG-Ndn). Cell 
lysates were immunoprecipitated (IP) with antibodies to FLAG and Myc, and 
immunoblotted (IB) for Myc, FLAG, and γ-tubulin (γ-Tub). Asterisks indicate 
non-specific IgG bands.  
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Figure III.6 Necdin interacts with the tyrosine kinase domain of EGFR. 
(A) Diagrams of EGFR and its C-terminal-truncated mutants. WT, wild-type; KR, 
K723R mutant; ΔC126, C-terminal 126 residue deletion; ΔC240, C-terminal 240 
residue deletion; ΔC497, C-terminal 497 residue deletion; TM, transmembrane domain; 
TKD, tyrosine kinase domain; Y, autophosphorylated tyrosine residues.  
(B) HEK293A cells were co-transfected with cDNAs for Myc-tagged EGFR (WT, KR) 
and necdin. Cell lysates were immunoprecipitated (IP) with antibodies to Myc and 
necdin, and immunoblotted (IB) for necdin, Myc, and γ-tubulin (γ-Tub). Results are 
shown in A.  
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Figure III.7 Necdin strongly interacts with the C-terminal 30 residues of 
EGFR tyrosine kinase domain. 
(A) Diagrams of TKD deletion mutants. TKD-WT, wild-type TKD; TKD-KR, K723R 
mutant TKD; TKDΔC91, C-terminal 91 residue deletion; TKDΔC30, C-terminal 30 
residue deletion; TKD-C91, C-terminal 91 residues; TKD-C30, C-terminal 30 residues; 
PL, phosphate-binding loop; CH, C-helix; AL, activation loop. (B) 
Coimmunoprecipitation assay for TKD-deletion mutants. HEK293A cells were 
co-transfected with cDNAs for Myc-tagged TKD mutants and necdin. Cell lysates were 
immunoprecipitated (IP) with antibodies to Myc and necdin and immunoblotted (IB) for 
necdin and Myc. Results are shown in A.  
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Figure III.8 Necdin directly binds to the C-terminal 30 residues of EGFR  
tyrosine kinase domain. 
(A) Diagrams of TKD deletion mutants. TKD-WT, wild-type TKD; TKDΔC30, 
C-terminal 30 residue deletion; TKD-C30, C-terminal 30 residues; PL, 
phosphate-binding loop; CH, C-helix; AL, activation loop. (B) In vitro binding assay. 
Purified maltose-binding protein (MBP)-fused EGFR deletion mutants immobilized on 
amylose resin were incubated with His-tagged necdin (His-Necdin). Bound His-necdin 
was detected by immunoblotting with anti-necdin antibody (upper panel). MBP-EGFR 
TKD mutants were separated by 7.5% SDS-PAGE and stained with Coomassie Brilliant 
Blue (lower panel). Results are shown in A. 
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Figure III.9 Necdin suppresses the EGFR/ERK signaling pathway in 
CPCs.  
(A, B) EGF-induced phosphorylation of EGFR, ERK, and Akt. CPCs prepared from 
wild-type (Ndn WT) and necdin-null (Ndn KO) mice at E14.5 were cultured for 4 days 
and treated with EGF (10 ng/ml) for the indicated durations. CPC lysates were 
immunoblotted for phospho-EGFR (pEGFR), EGFR, phospho-ERK (pERK), ERK, 
phospho-Akt (pAkt), Akt, necdin, and γ-tubulin. pEGFR, pERK and pAkt levels were 
quantified by densitometry and normalized to those of EGFR, ERK and Akt, 
respectively, and then to γ-tubulin (B). Each value represents the mean ± SEM, n = 3 
(pEGFR), n = 4 (pERK, pAkt). P-values were calculated using one-way ANOVA 
followed by Tukey-Kramer post hoc test.  
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Figure III.10 Necdin inhibits the interaction between EGFR and Grb2/Sos1 
in CPCs.  
(A, B) Interactions of EGFR with Grb2 and Sos1 in EGF-stimulated CPCs. CPCs at 4 
DIV were treated with (EGF+) or without (EGF-) EGF for 5 min. CPC lysates were 
immunoprecipitated (IP) with antibodies to Grb2 and Sos1 and immunoblotted (IB) for 
EGFR, Grb2, Sos1, pEGFR, pERK, ERK, necdin, and γ-tubulin (A). Signal densities of 
EGFR coprecipitated with Grb2 and Sos1 were normalized to those of Grb2 and Sos1, 
respectively, and then to γ-tubulin (B). Each value represents the mean ± SEM (Grb2, n 
= 6; Sos1, n = 4). P-values were calculated using Student's t-test.  
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Figure III.11 Necdin fails to interact with Grb2. 
Interaction between necdin and Grb2. HEK293A cells were transfected with cDNAs for 
Myc-tagged p53 (Myc-p53, positive control) and its N-terminal truncated mutant 
p53ΔN (Myc- p53ΔN, negative control)(Taniura et al., 1999) and Myc-tagged Grb2 
(Myc-Grb2) and Myc-tagged necdin (Myc-Ndn). Cell lysates were immunoprecipitated 
(IP) with antibodies to FLAG and Myc, and immunoblotted (IB) for Myc, FLAG, and 
γ-tubulin (γ-Tub).  
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Figure III.12 Necdin suppresses EGF-promoted proliferation of CPCs.   
(A, B) Total CPC count. CPCs prepared from wild-type (Ndn WT) and necdin-null 
(Ndn KO) E14.5 mice were cultured for 48 h, replated at 2 x 105 cells per 35-mm dish, 
and cultured in the presence (EGF+) or absence (EGF-) of EGF for another 48 h (A). 
Cells were harvested for manual cell counting (n = 4) and presented as fold change (B). 
P-values were calculated using one-way ANOVA followed by Tukey-Kramer post hoc 
test. NS, not significant at P ≥ 0.05. 
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Figure III.13 The population of EdU+ S-phase cells in necdin-null CPCs 
increased significantly.  
(A-C) EdU incorporation assay. CPCs were cultured for 96 h, replated onto 
poly-L-ornithine-precoated 24-well plates, cultured in the presence (EGF+) or absence 
(EGF-) of EGF for 24 h, and fixed for fluorescence microscopy (B). EdU was added to 
the medium 4 h before fixation, and EdU incorporated into nuclear DNA was 
chemically stained (green, arrowheads). EdU+ cells were counted (each >190 
DNA-stained cells examined, n = 3), and the EdU+ population is presented as 
percentage (C). P-values were calculated using one-way ANOVA followed by 
Tukey-Kramer post hoc test. NS, not significant at P ≥ 0.05. 
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Figure III.14 Expression of immediate early genes in wild-type and 
necdin-deficient CPCs. 
Expression levels of the immediate early genes cFOS, cJUN, EGR1, EGR2, and IEX1 
in EGF-treated CPCs prepared from wild-type (Ndn WT) and necdin-null (Ndn KO) 
mice were analyzed by qRT-PCR. P-values were calculated using one-way ANOVA 
followed by Tukey-Kramer post hoc test. n = 4. NS, not significant at P ≥ 0.05. 
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Figure III.15 Necdin suppresses EGF-promoted astrocyte differentiation of 
CPCs. 
(A-C) Astrocyte differentiation assay. CPCs prepared from wild-type (Ndn WT) and 
necdin-null (Ndn KO) mice at E14.5 were cultured for 48 h, treated with (EGF+) or 
without (EGF-) EGF for 48 h, and then with CT-1 for 48 h (A). CPCs were 
immunostained for GFAP (green)(B), and GFAP+ cells were counted (each >170 cells 
examined, n = 3)(C). (D) Expression of GFAP in CPCs treated with EGF in the 
presence (CT-1+) or absence (CT-1-) of CT-1 was analyzed by immunoblotting. 
Immunostained images are merged with nuclear DNA stain (B). Scale bar, 50 µm (in B). 
Each value represents the mean ± SEM (in C). P-values were calculated using one-way 
ANOVA followed by Tukey-Kramer post hoc test. NS, not significant at P ≥ 0.05. 
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Figure III.16 Necdin fails to affect neuronal differentiation. 
(A-C) Neuronal differentiation assay. CPCs were cultured for 48 h, treated with (EGF+) 
or without (EGF-) EGF for 48 h and incubated in the medium deprived of EGF and 
bFGF for 24 h (A). CPCs were immunostained for βIII-tubulin (red)(B), and 
βIII-tubulin + cells were counted (each >300 cells examined, n = 3)(C). Immunostained 
images are merged with nuclear DNA stain (B). Scale bar, 50 µm (in B). Each value 
represents the mean ± SEM (in C). P-values were calculated using one-way ANOVA 
followed by Tukey-Kramer post hoc test. NS, not significant at P ≥ 0.05. 
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Figure III.17 Expression of the GFAP protein and EGF mRNA in 
necdin-null neocortex in vivo.  
(A, B) GFAP protein levels in the neocortex in vivo. Neocortical tissues were prepared 
from wild-type (Ndn WT) and necdin-null (Ndn KO) mice at postnatal day 4 (P4). 
GFAP protein levels were analyzed by Western blotting and quantified by densitometry 
(B). Each value represents the mean ± SEM, n = 3. P-values were calculated using 
Student's t-test. (C, D) EGF mRNA levels. Expression levels of EGF in the neocortex at 
E18.5 (C) and primary CPCs at 4 DIV (D) were analyzed by quantitative RT-PCR 
(qRT-PCR). Each value represents the mean ± SEM (neocortex; n = 5, CPCs; n =3). 
P-values were calculated using Student's t-test. 
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Figure III.18 EGF-promoted astrocyte differentiation is mediated by the 
EGFR/ERK signaling pathway in CPCs. 
(A) Effects of kinase inhibitors on EGFR signaling pathways. CPCs were incubated for 
48 h and treated with EGF for 5 min. EGFR tyrosine kinase inhibitor (ETKI, gefitinib; 5 
µM), MEK inhibitor (MEKI, U0126; 20 µM) and PI3K inhibitor (PIKI, LY294002; 20 
µM) were added to the medium 30 min before EGF treatment. Phospho-EGFR 
(pEGFR), phospho-ERK (pERK), and phospho-Akt (pAkt) levels in CPCs were 
analyzed by immunoblotting. (B, C) GFAP expression in CT-1-treated CPCs. CPCs 
were cultured for 48 h, treated with EGF (EGF+) or without (EGF-) EGF and kinase 
inhibitors for 6 h, and incubated with CT-1 for 48 h (B). GFAP expression in CPCs was 
analyzed by immunoblotting (C).  
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Figure III.19 Necdin suppresses EGF-promoted GFAP expression in CPCs. 
(A, B) Effects of kinase inhibitors on GFAP levels in necdin-null CPCs. CPCs prepared 
from wild-type (Ndn WT) and necdin-null (Ndn KO) E14.5 mice were treated with EGF 
and kinase inhibitors as in Fig III.18B. Expression of GFAP, necdin, and γ-tubulin 
(γ-Tub) was analyzed by immunoblotting (A) and quantified by densitometry (B). 
GFAP levels were normalized to γ-tubulin levels. Each value represents the mean ± 
SEM, n = 4. P-values were calculated using one-way ANOVA followed by 
Tukey-Kramer post hoc test. NS, not significant at P ≥ 0.05. 
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Figure III.20 Overexpression of EGFR induce autophosphorylation without 
EGF stimulation. 
(A) Diagrams of EGFR and its mutants. WT, wild-type EGFR; KR, EGFR K723R 
mutant; ΔNT, EGFR N-terminal (residues 6-273) deletion mutant; L1/2, ligand-binding 
domain 1/2 (Ligand BD) ; TM, transmembrane domain; Necdin BD, necdin-binding 
domain; TKD, tyrosine kinase domain; CT, C-terminal domain. (B) 
Autophosphorylation of EGFR and ΔNT mutant. CPCs were transiently transfected 
with wild-type EGFR, KR mutant and ΔNT mutant by electroporation, and expression 
of phospho-EGFR (pEGFR) and EGFR in transfected CPCs was analyzed 12 h after 
transfection by immunoblotting. Tmt, td-Tomato vector control.  
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Figure III.21 Overexpression of EGFR enhances astrocyte differentiation. 
(A-C) GFAP expression in EGFR-overexpressing CPCs. CPCs were transiently 
transfected with cDNAs for wild-type EGFR and its mutants, cultured for 24 h, and 
treated with CT-1 for 48 h (A). GFAP expression in transfected CPCs was analyzed by 
triple staining of GFAP (green), td-Tomato (red), and nuclear DNA (blue)(D) and 
immunoblotting (B). Triple-stained images are merged for GFAP expression in 
td-Tomato+ cells (yellow in C). Arrowheads point to td-Tomato+ CPCs. Scale bar, 20 
µm.  
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Figure III.22 Necdin suppresses EGFR- and EGFRΔNT-promoted astrocyte 
differentiation of CPCs  
(A, B) Effect of necdin on EGFR-induced GFAP expression. CPCs were transiently 
transfected with combinations of cDNAs for wild-type EGFR, EGFRΔNT, 
FLAG-necdin (Ndn) and NdnΔEB (EGFR binding-defective necdin mutant). GFAP 
expression in transfected CPCs was analyzed immunoblotting (A). 
Necdin-immunoreactive bands at 46, 42, 34 kDa are of FLAG-necdin, endogenous 
necdin, and necdinΔEB, respectively. GFAP expression was quantified by densitometry 
(B). The broken line indicates the basal GFAP expression in CPCs expressing 
td-Tomato alone (=1). Each value represents the mean ± SEM, n = 4. P-values were 
calculated using one-way ANOVA followed by Tukey-Kramer post hoc test. NS, not 
significant at P ≥ 0.05. 
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Figure III.23 EGFR binding activities of necdin deletion mutants. 
(A) Diagrams of wild-type necdin (Necdin WT) and its deletion mutants. The necdin 
deletion mutants (NecdinΔ144-184, NecdinΔ191-222) reported previously (Taniura et 
al., 2005) were examined for the EGFR-binding activity. MHD, MAGE homology 
domain. (B) HEK293A cells were transfected with cDNAs for Myc-tagged EGFR, 
EGFR KR, necdin, and its mutants. Cell lysates were immunoprecipitated (IP) with 
antibodies to necdin and Myc, and immunoblotted (IB) for Myc, necdin, and γ-tubulin 
(γ-Tub) as in Fig. 4B. 
 
 
 
A B
Necdin WT
Necdin6144-184
Necdin6191-222
MHD
3251
222191
184144 IP: Necdin
IB: Myc
IP: Myc
IB: Necdin
Necdin
a-Tub
EGFR WT-Myc
EGFR KR-Myc
+- ++
-+ --
Necdin WT
Necdin6144-184
+ +
+ -- -
- -
245
kDa
48
245 
41
39
41
39
36
Myc
Necdin6191-222 - +- -
 57 
 
 
 
 
 
 
 
 
 
 
 
Figure III.24 MAGEA1 interacts with EGFR in an autophosphorylation 
independent manner. 
(A) Diagrams of EGFR and its C-terminal-truncated mutants. WT, wild-type; KR, 
K723R mutant; ΔC126, C-terminal 126 residue deletion; ΔC240, C-terminal 240 
residue deletion; ΔC497, C-terminal 497 residue deletion; TM, transmembrane domain; 
TKD, tyrosine kinase domain; Y, autophosphorylated tyrosine residues.  
(B) HEK293A cells were co-transfected with cDNAs for Myc-tagged EGFR mutants, 
FLAG-tagged necdin (positive control) and FLAG-tagged MAGEA1. Cell lysates were 
immunoprecipitated (IP) with antibodies to Myc and FLAG, and immunoblotted (IB) 
for FLAG, Myc, and γ-tubulin (γ-Tub). Results are shown in A.  
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Figure III.25 MAGEA1 interacts with the tyrosine kinase domain. 
(A) Diagrams of TKD deletion mutants. TKD-WT, wild-type TKD; TKDΔPL, 
phosphate-binding loop deletion; TKDΔCH, C-helix deletion; TKDΔAL, activation 
loop deletion; TKDΔC91, C-terminal 91 residue deletion. (B) Coimmunoprecipitation 
assay for TKD-deletion mutants. HEK293A cells were co-transfected with cDNAs for 
Myc-tagged TKD mutants and FLAG-tagged MAGEA1. Cell lysates were 
immunoprecipitated (IP) with antibodies to FLAG and immunoblotted (IB) for Myc, 
FLAG, and γ-tubulin (γ-Tub). Results are shown in A.  
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Figure III.26 MAGEA1 enhances EGFR-induced GFAP expression in 
primary CPCs. 
(A, B) Effects of necdin and MAGEA1 on EGFR-induced GFAP expression. CPCs 
were transfected with combinations of cDNAs for EGFR, FLAG-Ndn and 
FLAG-MAGEA1. GFAP expression in transfected CPCs was analyzed immunoblotting 
(A) and quantified by densitometry (B). FLAG-tagged and endogenous necdin proteins 
are detected at 46 and 42 kDa, respectively. The broken line indicates the basal GFAP 
level in CPCs expressing td-Tomato alone (=1). Each value represents the mean ± SEM, 
n = 3. P-values were calculated using one-way ANOVA followed by Tukey-Kramer 
post hoc test.  
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Figure III.27 The increase in the GFAP level was completely suppressed by 
coexpression of necdin, but not of necdinΔEB. 
(A, B) Effect of endogenous necdin on GFAP expression induced by EGFR 
overexpression. CPCs prepared from wild-type (Ndn WT) and necdin-null (Ndn KO) 
mice at E14.5 were transfected with EGFR, FLAG-necdin (Ndn) and NdnΔEB, and 
GFAP expression levels were analyzed. Each value represents the mean ± SEM, n = 4. 
P-values were calculated using one-way ANOVA followed by Tukey-Kramer post hoc 
test. NS, not significant at P ≥ 0.05. 
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IV. DISCUSSION 
IV-1. RAS/MEK/ERK signaling pathway and gliogenesis 
 EGFR signaling in CPCs plays an important role in astrocyte differentiation during 
the late embryonic period when the transition from neurogenesis to gliogenesis occurs 
in developing cortex (Temple, 2001). CPCs show little or no reactivity to EGF at early 
stages of embryonic cortical development (Tropepe et al., 1999; Qian et al, 2000; Zhu 
and Parada, 2002; Gritti et al., 1999). As the development proceeds, the bFGF level 
becomes high and induces EGFR expression in CPCs (Qian et al., 1997; Powell et al., 
1991). Mice lacking EGFR develop a progressive neurodegeneration and defect in 
cortical astrocytes (Wagner et al., 2006). Furthermore, the RAS/ERK signaling pathway 
is involved in astrocyte differentiation during brain development (Dasgupta and 
Gutmann, 2005; Li et al., 2014; Li et al., 2012; Wang et al., 2012). These findings 
indicate that the RAS/MEK/ERK signaling pathway is involved in the control of 
astrocyte differentiation during cortical development. Necdin suppresses the 
EGFR/ERK signaling pathway by interacting with autophosphorylated EGFR in 
EGF-responsive CPCs. Furthermore, the EGFR-inducible immediate early gene IEX-1 
(also known as IER3) induces astrocyte differentiation in human glioma cells (You et 
al., 2007). In the present study, IEX1 mRNA and GFAP expression levels increase 
significantly in EGF-treated necdin-null CPCs. Thus, we propose that necdin is an 
intrinsic suppressor of the EGF/EGFR signaling in CPCs to restrict astrocyte 
differentiation during the late period of cortical development. 
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IV-2. Structural changes of inactive and active EGFR 
 Stimulation of EGFR by EGF induces autophosphorylation of the C-tail followed 
by activation of downstream signaling pathways including the RAS/MEK/ERK and 
PI3K/Akt cascades (Jorissen et al., 2003). Activation of EGFR induces conformational 
changes of the ATP binding pocket between the N-lobe and the C-lobe in the TKD core 
region. The conformational change from “close” to “open” status is regulated by 
C-helix movement, which is coupled with the motions of the juxtamembrane segment 
that connects the transmembrane helix to the TKD and the C-tail segment (Jura et al., 
2009; Mustafa et al., 2011). This may allosterically control the autophosphorylation of 
the C-tail. Necdin suppresses the EGFR/ERK signal transduction by interacting with the 
C-terminal region of the TKD. Necdin interacts with the TKD of EGFR only in its 
activated state, and the interaction is enhanced in the absence of the C-tail. This 
suggests that the unphosphorylated C-tail interferes with the interaction between necdin 
and the TKD (Fig IV.1). This idea is supported by the previous observations on the 
conformational changes of the C-tail and TKD in inactive and active states of EGFR 
(Jura et al., 2009; Mustafa et al., 2011). We speculate that necdin binds to the TKD 
when autophosphorylation of the C-tail uncovers the necdin-binding site on the TKD 
(Fig IV.2A,B). Thus, the C-tail may serve as a molecular switch to control the 
interaction between necdin and the TKD in CPCs.  
 
IV-3. Difference between necdin and MIG6 
 The TKD of EGFR consists of N-terminal (N-lobe) and C-terminal (C-lobe) 
regions, and the N-lobe contains the specific sites for the tyrosine kinase activity such as 
ATP-binding site, C-helix, and phosphate-binding loop (P-loop) (Lemmon et al., 2014; 
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Zhang et al., 2006) (Fig IV.2A). Necdin binds to the C-terminal end of the C-lobe, and 
this location may be critical for the reduced interaction between autophosphorylated 
C-tail and Grb2 without affecting the tyrosine kinase activity. Intriguingly, the EGFR 
feedback inhibitor MIG6 (also known as RALT or ERRFI1), like necdin, binds to the 
TKD when EGFR is activated (Zhang et al., 2007). However, MIG6, unlike necdin, is 
transiently expressed by EGFR ligands and inhibits the tyrosine kinase activity to 
suppress both RAS/ERK and PI3K/Akt pathways (Segatto et al., 2011). This may be 
attributable to the structural characteristics of MIG6 associated with the allosteric 
control of the EGFR kinase activity (Anastasi et al., 2007; Zhang et al., 2007). The 
differences between necdin and MIG6 imply that necdin is a unique inhibitor of the 
EGFR/RAS/ERK signaling pathway linked to cellular proliferation but not of the 
PI3K/Akt signaling pathway linked to cell survival. These findings are consistent with 
the notion that necdin suppresses cell proliferation and maintains cell survival. 
 
IV-4. Neurogenesis and gliogenesis in cortical development 
 Neural precursor cells in the embryonic forebrain of necdin-null mice are highly 
proliferative in vivo during the early period of development when neurogenesis occurs 
actively (Huang et al., 2013; Minamide et al., 2014). Necdin suppresses the proliferation 
of CPCs by increasing p16 expression through interaction with the p16 transcriptional 
repressor Bmi1 and by reducing Cdk1 expression through interaction with the Cdk1 
transcriptional activator E2F1 (Minamide et al., 2014), suggesting that necdin prevents 
hyperproliferation of early CPCs, which are competent to differentiate into neurons, by 
modulating the activities of these cell cycle regulatory proteins. The present study 
provides evidence that necdin suppresses astrocyte generation from EGF-responsive 
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CPCs through attenuation of the EGFR/ERK pathway. Thus, necdin may control the 
EGFR/ERK signaling pathway in late CPCs, which are competent to differentiate into 
astrocytes. We propose that necdin fine-tunes the regulatory systems involved in 
neurogenesis and gliogenesis at different stages of normal cortical development.  
 
IV-5. Implication in cancer pathogenesis 
 Numerous studies have indicated that EGFR signaling is central to the 
pathogenesis of many cancers such as glioblastoma, breast cancer and non-small-cell 
lung cancer (NSCLC), in which genetic alterations of EGFR such as gene amplification 
and mutations may be involved (Normanno et al., 2006; Sibilia et al., 2007). 
Furthermore, the importance of EGFR signaling in cancer progression is supported by 
the fact that several anticancer drugs such as gefitinib and erlotinib target the EGFR 
TKD (Herbst et al., 2004). The present study has clarified that necdin acts as an 
endogenous suppressor of EGFR signaling. Furthermore, necdin is not expressed in 
many cancer cells, where the necdin gene is hypermethylated and mutated (De Faveri et 
al., 2013). These findings raise the possibility that necdin potentially suppresses 
malignant transformation induced by increased EGFR signaling in various types of 
cancers. As shown in this study, necdin suppresses EGFR overexpression-induced 
astrocyte differentiation, whereas MAGEA1, another MAGE family member expressed 
in many kinds of malignant tumors (Chomez et al., 2001), promotes it, suggesting that 
necdin and MAGEA1 exert opposite effects on EGFR-mediated signaling events. Thus, 
it is tempting to speculate that these different types of MAGE family members 
antagonistically control malignant transformation induced by EGFR or its mutants. 
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IV-6. Implication in gliomagenesis 
 Dysregulation of EGFR signal transduction has been suggested to contribute to the 
etiology of brain tumors including gliomas (Nicholas et al., 2006). Aberrant activation 
of the RAS/MEK/ERK pathway is also involved in the pathogenesis of astrocytoma or 
glioma (Li et al., 2014; Zhu and Parada, 2002). On the other hand, necdin is not 
expressed in many cell lines derived from neural cell-derived tumors such as glioma, 
neuroblastoma, pheochromocytoma, and ependymoma (Aizawa et al., 2011; Aizawa et 
al., 1992; Kobayashi et al., 2002). A network modeling study of DNA copy number 
aberrations implicates necdin in suppressing cell growth of glioblastomas (Jornsten et 
al., 2011). Furthermore, reduced NDN expression in low grade gliomas strongly 
correlates with reduced overall survival of patients with gliomas (Li et al., 2015). The 
gene overexpression experiments demonstrated that necdin strongly prevents astrocyte 
differentiation induced by overexpression of wild-type EGFR or its mutant equivalent 
to human EGFR variant III (EGFRvIII) in CPCs. Overexpression of EGFR and its 
deletion mutants such as EGFRvIII is commonly found in glioblastomas (Nicholas et al., 
2006). Gliomas are proposed to arise from neural stem cells that are generated from 
glial progenitor cells or astrocytes via reprogrammed processes (Sanai et al., 2005; Zhu 
and Parada, 2002). Thus, we infer that necdin serves as a tumor suppressor that controls 
the EGFR/ERK pathway in astrocyte progenitors to prevent their malignant 
transformation.  
 
IV-7. Implication in pathogenesis of Prader-Willi syndrome 
 The human necdin gene (NDN) is located in chromosome 15q11.2-q12 (Nakada et 
al., 1998), a region deleted in Prader-Willi syndrome (PWS), a typical genomic 
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imprinting-associated neurodevelopmental disorder. NDN is maternally imprinted, 
expressed only from the paternal allele, and not expressed in individuals with PWS (Jay 
et al., 1997; MacDonald and Wevrick, 1997). Although patients with PWS exhibit 
symptoms due to hypothalamic abnormalities such as hyperphagia and hypogonadism, 
there is limited information on neuropathological lesions in PWS. In contrast, the mouse 
necdin gene (Ndn) located in chromosome 7C is also imprinted, and paternal 
Ndn-mutant mice display failure-to-thrive and early neonatal lethality (Gérard et al., 
1999; Muscatelli et al., 2000). Moreover, PWS model mice created by transgene 
insertion or PWS imprinting-center mutation fail to express necdin and display early 
postnatal lethality (Gabriel et al., 1999; Yang et al., 1998). The Ndn-mutant mice, 
mostly examined at their embryonic and neonatal stages, exhibit various morphological 
and functional abnormalities, in which several are reminiscent of PWS (Aebischer et al., 
2011; Bush and Wevrick, 2010, 2012; Fujiwara et al., 2012; Hasegawa et al., 2012; 
Kuwajima et al., 2010; Kuwajima et al., 2006; Kuwako et al., 2005; Miller et al., 2009; 
Muscatelli et al., 2000; Ren et al., 2003; Tennese et al., 2008; Zanella et al., 2008). Thus, 
primary cells such as CPCs prepared from necdin-null mice are indispensable for 
dissecting molecular mechanisms underlying these abnormalities. We assume that other 
stem/progenitor cells expressing both necdin and EGFR also exhibit enhanced EGFR 
signaling in the absence of endogenous necdin. The present findings warrant close 
examination of the pathologies associated with dysregulation of EGFR signaling in 
PWS. 
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Figure IV.1 A schematic model for suppression of EGFR signaling by 
necdin. 
Necdin binds to EGF-activated EGFR via the TKD C-lobe and blocks the interaction 
between EGFR and Grb2, resulting in the suppression of the RAS/ERK signaling 
pathway. For details, see Discussion. ICD, intracellular domain; TKD, tyrosine kinase 
domain; P, phospho-tyrosine; Ndn+, wild-type necdin; Ndn-, necdin deficiency. 
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Figure IV.2 Ribbon representation of the crystalized conformations of 
EGFR TKD and predicted structure of necdin MHD. 
(A) Crystal structures of inactive EGFR TKD (PDB 4G5J)(left) and active EGFR TKD 
in complex with ATP analog-peptide (PDB 2GS6)(right). Yellow; necdin-binding 
region. (B) A predicted necdin MHD structure. The structural model was predicted on 
the basis of structural data of necdin-like 2 (PDB 3NW0) by the Spanner program and 
presented by UCSF Chimera. Yellow; EGFR-binding region.  
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CONCLUSIONS 
 
  
l EGFR and necdin are coexpressed in primary CPCs.  
l Necdin binds to autophosphorylated EGFR via its tyrosine kinase domain.  
l The EGFR/ERK pathway is activated in necdin-null CPCs through increased 
interaction between EGFR and Grb2.  
l EGF-promoted astrocyte differentiation is accelerated via the EGFR/ERK pathway 
in necdin-null CPCs.  
l Necdin restrains astrocyte differentiation induced by overexpression of EGFR or 
its EGF binding-defective mutant in CPCs.  
l Necdin is an intrinsic suppressor of EGFR/ERK signaling in CPCs under 
physiological and pathological conditions.  
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